Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Trading Cabana -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Podsiadlik who wrote (5462)	5/11/2009 1:40:37 PM
From: RockyBalboa	Read Replies (2) \| Respond to of 6370

The microcap biotechs are going nuts. Look what GNTA is doing. I lost count on the OS shares of GNTA but there must be billions out. Re HEB.. any chance that they bribe a "yes" out of the FDA? Clock is definitely ticking.

To: Kevin Podsiadlik who wrote (5462)	5/19/2009 9:30:01 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 6370

Look, "not wasting time" stock lower again, PHILADELPHIA, May 19, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced today that it has agreed to sell up to $16 million in common stock and warrants in a registered offering to two institutional investors. The investors will purchase for $16 million cash, 11,906,976 common shares of its stock at $1.34375 per share. Related Quotes Symbol Price Change HEB 1.93 0.00 Investors will also receive warrants to purchase 4,167,442 shares of Hemispherx Biopharma, Inc.'s common stock. The warrants have an exercise price of $1.31 per share and are exercisable at any time after the closing of the transaction and before the fifth anniversary of such initial issuance date. The closing of the offering is expected to take place subject to the satisfaction of customary closing conditions, including the approval of an application for the listing of additional shares by the NYSE Amex exchange. Hemispherx Biopharma, Inc. plans to use the net proceeds from the offering to fund commercialization of Alferon N and for other research and development and general corporate purposes. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM:RODM - News), acted as the exclusive placement agent for this transaction. A shelf registration statement relating to the Common Stock and warrants to be issued in the offering, and to the common stock underlying the warrants, has been filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Hemispherx Biopharma, 1617 JFK Boulevard, Philadelphia, PA 19103. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock or associated warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful. About Hemispherx Biopharma